HF Advisory Group LLC Has $1.15 Million Holdings in McKesson Corporation $MCK

HF Advisory Group LLC cut its stake in McKesson Corporation (NYSE:MCK) by 30.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,516 shares of the company’s stock after selling 675 shares during the quarter. HF Advisory Group LLC’s holdings in McKesson were worth $1,146,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of MCK. University of Texas Texas AM Investment Management Co. bought a new position in shares of McKesson during the 4th quarter valued at approximately $25,000. Swiss RE Ltd. purchased a new position in shares of McKesson in the fourth quarter valued at $26,000. State of Wyoming purchased a new position in McKesson during the 2nd quarter valued at about $29,000. Kingdom Financial Group LLC. bought a new stake in McKesson during the 4th quarter worth approximately $33,000. Finally, Birchwood Financial Partners Inc. bought a new position in shares of McKesson in the fourth quarter worth $33,000. Hedge funds and other institutional investors own 85.07% of the company’s stock.

McKesson Trading Up 0.0%

Shares of NYSE:MCK opened at $871.72 on Friday. The stock’s 50-day moving average price is $800.68 and its 200-day moving average price is $840.98. McKesson Corporation has a 12-month low of $637.00 and a 12-month high of $999.00. The stock has a market capitalization of $101.63 billion, a P/E ratio of 23.33, a price-to-earnings-growth ratio of 1.43 and a beta of 0.30.

McKesson (NYSE:MCK) last released its earnings results on Wednesday, August 5th. The company reported $9.93 earnings per share for the quarter, beating analysts’ consensus estimates of $9.56 by $0.37. The company had revenue of $105.38 billion during the quarter, compared to analyst estimates of $103.88 billion. McKesson had a negative return on equity of 253.21% and a net margin of 1.12%.McKesson’s revenue for the quarter was up 7.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $8.26 EPS. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. As a group, research analysts predict that McKesson Corporation will post 44.59 EPS for the current year.

McKesson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 1st. Shareholders of record on Tuesday, September 1st will be given a $0.94 dividend. The ex-dividend date is Tuesday, September 1st. This is an increase from McKesson’s previous quarterly dividend of $0.82. This represents a $3.76 annualized dividend and a yield of 0.4%. McKesson’s dividend payout ratio is presently 10.06%.

Wall Street Analysts Forecast Growth

MCK has been the subject of several research analyst reports. Citigroup lifted their price objective on McKesson from $945.00 to $1,000.00 and gave the company a “buy” rating in a research note on Friday, July 24th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $875.00 price objective on shares of McKesson in a report on Friday, May 8th. Barclays lowered their target price on shares of McKesson from $1,050.00 to $925.00 and set an “overweight” rating on the stock in a research note on Wednesday, June 10th. UBS Group boosted their price target on shares of McKesson from $1,050.00 to $1,080.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Robert W. Baird set a $1,015.00 price objective on shares of McKesson in a research report on Thursday. Fourteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $968.93.

Insider Buying and Selling

In related news, CEO Brian S. Tyler sold 8,463 shares of the company’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $793.56, for a total transaction of $6,715,898.28. Following the completion of the sale, the chief executive officer directly owned 5,919 shares in the company, valued at $4,697,081.64. This represents a 58.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michele Lau sold 3,550 shares of the stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $761.09, for a total transaction of $2,701,869.50. Following the sale, the executive vice president directly owned 3,247 shares of the company’s stock, valued at $2,471,259.23. The trade was a 52.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 28,748 shares of company stock worth $22,262,035. 0.06% of the stock is owned by company insiders.

McKesson News Summary

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Quarterly results exceeded expectations. McKesson reported adjusted earnings of $9.93 per share, ahead of the $9.44-$9.56 analyst consensus range, while revenue rose 7.7% year over year to $105.38 billion, topping estimates. EPS also increased from $8.26 in the prior-year quarter. McKesson Q1 Earnings and Revenues Top Estimates
• Positive Sentiment: Specialty pharmaceutical growth drove profitability. Pharma profit rose 19%, supported by specialty medicine demand and oncology growth. Management raised fiscal 2027 adjusted EPS guidance to $44.20-$45.00, broadly in line with or above current analyst expectations. MCK Q1 Earnings Call Centers on Pharma-Led Guidance Raise
• Positive Sentiment: Capital returns are becoming more attractive. McKesson plans approximately $5 billion in share repurchases and raised its dividend by 15%, potentially supporting per-share earnings and investor sentiment. McKesson Outlines Fiscal 2027 EPS and Share Repurchases
• Neutral Sentiment: McKesson is rebranding its Medical-Surgical Solutions business as Wellverse ahead of a planned spinoff and potential IPO. The move could unlock value, although it also introduces execution and separation risks. McKesson Debuts Wellverse Name
• Neutral Sentiment: Recent Zacks commentary characterizes MCK as a growth stock, citing earnings growth, specialty-drug exposure and improving fundamentals. However, these articles are analytical opinions rather than new company announcements. McKesson Is an Incredible Growth Stock

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.